ClinicalTrials.gg
Sign In
RecruitingNCT07303712Updated Dec 26, 2025

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

An observational study in Hepatocellular Carcinoma (HCC), sponsored by Palo Alto Veterans Institute for Research. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Palo Alto Veterans Institute for Research · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Read the detailed description

Study Aims and Objectives:

  1. Assess the detection rate of CTC and cfDNA-based mutations and the distribution of molecular features of HCC prior to Y90 across BCLC A-C stages.
  2. Determine CTC and cfDNA predictors at baseline that predict Y90 treatment response at 6-9 months.
  3. Determine temporal changes in CTC and cfDNA mutations from baseline over 6-9 month course post Y90.
  4. Determine if CTC mean distribution, sCTCDNA, and/or cfDNA mutational dynamic changes are predictive of treatment response at 6-9 months.
  5. Assess radiomic and liquid biopsy signatures associated with outcome
  6. Compare predictive outcome models using liquid biopsy data, imaging data, or a combination (multiomic data)
02

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • Circulating tumor cell (CTC)
  • y90
03

In context

Carcinoma, Hepatocellular

3,648 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,061 are open to participants now.

This study's planned enrollment of 12 is below the median of 200 across 850 observational studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Palo Alto Veterans Institute for Research is the lead sponsor of 53 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients at VAPAHCS with HCC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > or = 18 years
  2. HCC confirmed on imaging, BCLC stage 0, A, B, or C
  3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board -

Exclusion criteria

Exclusion Criteria:

  1. Not eligible for Y90 procedure
  2. Prior surgery or ablation on indicated tumors
  3. Patient unable to complete the follow up visits required for clinical care or research -
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Circulating Tumor Cell (CTC)

    blood samples

    Time frame: Baseline, 1 month post treatment, 3 months post treatment, and 6 months post treatment

  2. CTA imaging

    imaging of liver tumor

    Time frame: Baseline, 3 months post treatment, 6 months post treatment

07

Study locations

1 of 1 sites recruiting
  • VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
    Recruiting
    • Sirish Kishore, MD · Contact650-493-5000
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07303712
Lead sponsor
Palo Alto Veterans Institute for Research
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Aug 1, 2024
Primary completion
Aug 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Sirish Kishore, MD
Contact
sirish.kishore@va.gov
650-493-5000 ext. 61706
Luisa Manfredi, MPH
Contact
luisa.manfredi1@va.gov
650-493-5000 ext. 61706
Sirish Kishore, MD
principal investigator · VA Palo Alto Health Care System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma, Hepatocellular →

Other studies from this sponsor

Palo Alto Veterans Institute for Research

Start the discussion